title: Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.
abstract: The activating BRAF mutation p.V600E has been identified in many cancers, including colon and lung adenocarcinomas, papillary thyroid cancer, malignant melanoma, and hairy cell leukemia (HCL). Malignant melanoma and HCL are of particular interest because of both the high proportion of cases harboring the mutation and the dramatic responses to BRAF inhibitor therapy reported in the literature. This report presents a patient with HCL and malignant melanoma with the BRAF p.V600E mutation, and discusses the successful treatment of both cancers with the BRAF inhibitor dabrafenib.
authors.affiliation: From the Division of Hematology, Department of Internal Medicine, Department of Pathology, and Division of Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio.
authors.forename: James S
authors.initials: JS
authors.lastname: Blachly
authors.affiliation: From the Division of Hematology, Department of Internal Medicine, Department of Pathology, and Division of Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio.
authors.forename: Gerard
authors.initials: G
authors.lastname: Lozanski
authors.affiliation: From the Division of Hematology, Department of Internal Medicine, Department of Pathology, and Division of Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio.
authors.forename: David M
authors.initials: DM
authors.lastname: Lucas
authors.affiliation: From the Division of Hematology, Department of Internal Medicine, Department of Pathology, and Division of Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio.
authors.forename: Michael R
authors.initials: MR
authors.lastname: Grever
authors.affiliation: From the Division of Hematology, Department of Internal Medicine, Department of Pathology, and Division of Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio.
authors.forename: Kari
authors.initials: K
authors.lastname: Kendra
authors.affiliation: From the Division of Hematology, Department of Internal Medicine, Department of Pathology, and Division of Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio.
authors.forename: Leslie A
authors.initials: LA
authors.lastname: Andritsos
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology / Q000627:therapeutic use*; D007943:Leukemia, Hairy Cell / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008545:Melanoma / Q000175:diagnosis / Q000188:drug therapy*; D009154:Mutation; D016609:Neoplasms, Second Primary; D010091:Oximes / Q000494:pharmacology / Q000627:therapeutic use*; D049268:Positron-Emission Tomography; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors / Q000235:genetics; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D010091:Oximes; D047428:Protein Kinase Inhibitors; D048493:Proto-Oncogene Proteins B-raf; C561627:dabrafenib